MORE►
taysha
The main building at Pegasus Park.[Image: GFF]
Bridge Labs Expansion Coming to Pegagus Park in 2024
by Lance Murray | Feb 13, 2023
The new two-story lab and office building will offer "the first institutional-quality space" in the DFW market, according to marketing materials.
by Alex Edwards |
Apr 12, 2021
Taysha Gene Therapies, which rocketed from a UTSW spinout to a $157 million IPO in under six months last year, has gone global with rights to TSHA-120, a promising AAV9 clinical-stage gene therapy.
It's a historic announcement. There are no current treatments for giant axonal neuropathy, or GAN, a severe, progressive disease that affects the central and peripheral nervous systems. TSHA-120 is the first-ever successful in-human intrathecal (spinal) gene transfer.
It's a historic announcement. There are no current treatments for giant axonal neuropathy, or GAN, a severe, progressive disease that affects the central and peripheral nervous systems. TSHA-120 is the first-ever successful in-human intrathecal (spinal) gene transfer.
MORE►
by Quincy Preston |
Feb 26, 2021
In under six months, Taysha Gene Therapies rocketed from the unveiling of its UTSW spinout to a $157 million initial public offering. We talk with Founder and CEO R.A. Session II about the biotech with big plans.
MORE►
by Quincy Preston and Sandra Engelland |
Feb 24, 2021
With an entrepreneurial mindset, Aldridge turns scientific discoveries into real-world solutions. Here's how Aldridge is playing a large role in making Dallas a destination for biotech and life sciences.
MORE►
R.A. Session II, CEO and co-founder of Taysha Gene Therapies [Background image: Olena Yepifanova via iStock]
Taysha and UTSW Launch Innovation Fund to Advance the Development of New Gene Therapies
by Alex Edwards | Jan 13, 2021
The expanded alliance between Taysha and UTSW, which dates back to when Taysha emerged from stealth in April 2020, will support the discovery of novel gene therapy candidates and technologies in new disease areas.
MORE►
![R.A. Session II, president, CEO, and founder of Taysha Gene Therapies [Background image: Olena Yepifanova via iStock]](https://s24806.pcdn.co/wp-content/uploads/2020/04/TayshaGene-Session-970-1-360x203.jpg)
by Quincy Preston and Alex Edwards |
Aug 5, 2020
Taysha Gene Therapies, which was been operating in stealth with UT Southwestern until this April, plans to use the financing to advance its initial cohort of lead programs into its clinic. By the end of 2021, Taysha expects to file four Investigational New Drug applications.
MORE►
